Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

Mon, 01st Jul 2019 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith, up 1.7%. The paper and packaging firm said it completed the sale of two packaging businesses in north west France and in Portugal to Memphis, Tennessee-based peer International Paper for EUR63 million. DS Smith said the sale honours the commitment made to the European Commission in relation to the clearance of its acquisition of Spanish packaging firm Europac, which completed in January. Last month, DS Smith had said financial 2019, which ended on April 30, was a "year of good delivery" overall, with "substantial" progress being made overseas and the integration of Europac was going well. Fellow packaging firms Smurfit Kappa and Mondi were up 2.6% and 1.7%, respectively. ----------FTSE 100 - LOSERS----------Fresnillo, down 2.9%. The Mexican gold miner was tracking spot gold prices lower, quoted at USD1,390.28 an ounce, down sharply from USD1,411.62 late Friday. Last week, gold had touched a six-year high of USD1,438.63. Additionally, Fresnillo on Monday said it has decided to align tax treatment for all of the company's underground mining operations, resulting in a USD8.0 million impact on profit for the six months to June-end. Shares in midcap gold miners Centamin and Hochschild Mining also were being hurt by the lower gold price, down 2.2% and 1.7%, respectively.----------International Consolidated Airlines Group, down 1.2%. Bernstein downgraded the airlines operator to Market Perform from Outperform. ----------FTSE 250 - WINNERS----------Future, up 9.0%. The digital media and publishing firm said full-year results will be ahead of expectations, underpinned by good audience growth within the Media division and the continued strong performance of recent acquisitions. The guidance was also attributed to a continuation of positive trends seen in the first half. Future's financial year ends September and will report annual results in November. "Future has a platform which enables it to monetise specialist content through a mixture of e-commerce, getting content users to click through to partnered retailers, events and online advertising. The plan is to feed newly-acquired assets into this platform. Newspaper and magazine publishers continue to battle falling sales and have struggled to get readers to pay for their relatively generic content, but consumers have shown a greater willingness to pay for specialist and niche content which they are unable to get elsewhere," said AJ Bell's Russ Mould.----------FTSE 250 - LOSERS----------John Laing Group, down 1.0%. Barclays started coverage on the infrastructure project investor at Equal Weight. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Tiziana Life Sciences, up 14%. The biotechnology company noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes. The phase two study of Teplizumab, an anti-CD3 antibody similar to Foralumab being developed by Provention Bio, was published in the New England Journal of Medicine. Type-1 diabetes is caused by the immune system's T cells attacking insulin-producing cells in the body. Anti-CD3 antibodies like Tiziana's Foralumab and Provention Bio's Teplizumab suppress the immune system to prevent this from happening. Teplizumab is derived from mice and was injected intravenously in patients whose relatives already have type 1 diabetes. Of the 76 patients evaluated, 72% were under 18. The patients were randomised to receive either a 14-day course of Teplizumab or placebo and tested at six-month intervals. At the end of the Teplizumab trial, 57% of participants treated with the drug had not developed diabetes compared to 28% on the placebo.----------OTHER MAIN MARKET AND AIM - LOSERS----------Hurricane Energy, down 17%. The oil and gas explorer said it will abandon and plug the Warwick Deep well after it did not produce at commercial rates. Hurricane had drilled the offshore North Sea well to 1,964 metres, with results indicating a 712-metre horizontal section of fractured basement reservoir. However, initial analysis suggests the well found a "poorly" connected part of the fracture network within the oil column, and the well produced at non-commercial rates. Following plugging and abandoning Warwick Deep, Hurricane will move the rig to the Lincoln Crestal wall, the second of three wells on the Greater Warwick Area.----------

More News
4 Dec 2019 15:38

Tiziana initiates study of 'Foralumab' in coated capsule form

(Sharecast News) - Clinical-stage biotechnology company Tiziana Life Sciences announced the initiation of a phase 1 clinical trial in healthy volunteers on Wednesday, with a proprietary oral formulation of 'Foralumab' encapsulated in enteric-coated capsules.

Read more
4 Dec 2019 11:52

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Read more
20 Nov 2019 13:02

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Read more
1 Nov 2019 17:31

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Read more
30 Sep 2019 10:27

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Read more
16 Sep 2019 13:03

Tiziana Life Sciences Gets New Foralumab Formulation US Trial Approval

(Alliance News) - Tiziana Life Sciences PLC on Monday said the US Food & Drug Adminsitration has allowed the company to begin a phase 1 clinical trial of its novel Foralumab formulation in in

Read more
10 Sep 2019 14:34

Tiziana Life Sciences Announces Positive Data From Foralumab Trial

(Alliance News) - Tiziana Life Sciences PLC on Tuesday said data from its phase 1 trial of Foralumab showed the drug "was well-tolerated at all doses" and produced a positive biomarker a

Read more
4 Sep 2019 11:04

Encouraging Data From Tiziana Life Sciences Milciclib Cancer Study

(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced positive data from its study of Milciclib in patients with advanced liver cancer.Shares in Tiziana were up 19% at 57.00 in

Read more
22 Jul 2019 09:54

Tiziana Reports No Drug-Related Deaths In Milciclib Liver Cancer trial

(Alliance News) - Tiziana Life Sciences PLC on Monday said there were no drug related deaths in its phase 2a trial of Milciclib in advanced liver cancer and the drug was well tolerated with some 6

Read more
1 Jul 2019 10:20

Tiziana Notes Positive Study Of Drug Similar To Foralumab In Diabetes

(Alliance News) - Tiziana Life Sciences PLC on Monday noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes.Shares in the biotechnology company

Read more
1 May 2019 10:08

FDA asks Tiziana for more information on next 'foralumab' trial

(Sharecast News) - Biotechnology company Tiziana Life Sciences updated the market in its 'Investigational New Drug' (IND) application to the US Food and Drug Administration (FDA) on Wednesday, to initiate a phase 1 clinical trial of enteric-coated capsules of its 'foralumab' product in healthy volunteers.

Read more
24 Apr 2019 12:20

Most Patients Stick With Milciclib In Tiziana Life Sciences Study

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday reported encouraging interim data from its trial of milciclib in patients with advanced liver cancer.Shares in Tiziana were -

Read more
4 Apr 2019 10:58

Tiziana Life Sciences Annual Loss Narrows On Marginally Reduced Costs

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday reported a slight reduction in its annual loss as costs were reduced.For 2018, the clinical stage biotechnology company posted

Read more
20 Mar 2019 13:01

Tiziana Life Sciences Submits Application For Foralumab Trial In US

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it has submitted an application in the US to begin a phase one trial of its autoimmune and inflammatory disease drug new drug a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.